FDA Grants Approval for Milestone Pharma's CARDAMYST, the First Self-Administered Therapy for PSVT
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 13 2025
0mins
Source: NASDAQ.COM
FDA Approval: Milestone Pharmaceuticals Inc. received FDA approval for CARDAMYST (etripamil) nasal spray, a treatment for acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults.
Access to Treatment: The approval allows over two million Americans with PSVT to access a rapid-acting, self-administered treatment option outside of healthcare settings, enhancing their ability to manage episodes.
Product Availability: CARDAMYST is expected to be available in retail pharmacies starting in the first quarter of 2026.
Stock Performance: Following the announcement, MIST's stock closed at $2.41, a decline of 18.31%, but saw a slight recovery in after-hours trading to $2.46.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIST
Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.910
Low
8.00
Averages
8.00
High
8.00
Current: 1.910
Low
8.00
Averages
8.00
High
8.00
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CARDAMYST Nasal Spray Now Available at Retail Pharmacies
- Product Launch: Milestone Pharmaceuticals announces that its first commercial product, CARDAMYST™ (etripamil) nasal spray, is now available at U.S. retail pharmacies, marking a significant advancement in the cardiovascular drug market.
- Sales Force Deployment: The company plans to deploy a national sales force in mid-February 2026 to support product promotion and market penetration, which is expected to significantly enhance market coverage and sales potential.
- Patient Assistance Program: CARDAMYST will be supported by a comprehensive patient assistance platform offering benefits verification and reimbursement support, with a projected $25 copay cap for eligible commercially insured patients, thereby reducing financial burdens on patients.
- FDA Approval Milestone: CARDAMYST received FDA approval on December 12, 2025, becoming the first drug approved for treating paroxysmal supraventricular tachycardia (PSVT) in over 30 years, addressing a critical gap in effective treatment options.
Continue Reading
Milestone Pharmaceuticals (MIST) Receives EMA Review for Etripamil Nasal Spray
- Regulatory Progress: Milestone Pharmaceuticals' Marketing Authorization Application for Etripamil nasal spray has been accepted for review by the European Medicines Agency, with a decision expected in Q1 2027, potentially offering the first self-administered therapy for PSVT patients in Europe.
- Clinical Data Support: The application is backed by data from over 1,800 participants and more than 2,000 PSVT episodes, demonstrating that 64% of patients using Etripamil converted to sinus rhythm within 30 minutes, compared to only 31% in the placebo group, significantly enhancing treatment options and quality of life for patients.
- Significant Market Potential: As a fast-acting calcium channel blocker, Etripamil aims to provide patients with a reliable option to convert PSVT episodes outside of healthcare settings, which is expected to reduce the need for emergency visits and invasive ablation procedures, thereby alleviating the burden on healthcare systems.
- U.S. Market Performance: Etripamil was approved in the U.S. in December 2025 under the brand name CARDAMYST, with availability in retail pharmacies anticipated this quarter, further strengthening the company's market position in cardiac care.
Continue Reading